Early death from papillary thyroid carcinoma

Hamzany, Yaniv; Soudry, Ethan; Strenov, Yulia; Lipschitz, Noga; Segal, Karl; Hadar, Tuvia; Hilly, Ohad; Feinmesser, Raphael

doi:10.1016/j.amjoto.2011.04.002

Cited by 14 publications

(16 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the pathologic reports with comprehensive and detailed description, such as microscopic ETE or nodal metastasis, might enable pathologic characteristics to predict clinical outcomes more exactly. However, our retrospective study was limited by the fact that thyroid examinations did not occur using the same neck USG and 5by insufficient data in the pathologic reports. In the future, well-designed prospective studies are warranted.…”

Section: Discussionmentioning

confidence: 99%

“…However, some thyroid cancer patients still experience aggressive clinical outcomes (3,4,5,6); thus, it is important to understand the prognostic factors for a poor prognosis. Previous studies have reported older age, male sex, large tumor size, lymph node (LN) involvement, extrathyroidal extension (ETE), and distant metastasis as poor prognostic factors (7).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Secular trends in the prognostic factors for papillary thyroid cancer

Choi

Lim

Ahn

et al. 2014

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: With the recent increasing rates of screening for thyroid cancer, the cancers now tend to be smaller and less aggressive than those that are diagnosed when presented with symptoms, suggesting changes in the clinical validity of conventional prognostic factors for outcomes. We performed the retrospective study to identify the secular trends in the prognostic factors of thyroid cancer. Methods: We used medical records of 3147 patients diagnosed with papillary thyroid cancer (PTC) at the Seoul National University Hospital Thyroid Cancer Clinic between 1962 and 2009. Results: During the median 5.1-year follow-up, the overall recurrence rate was 13.3%, and male sex, tumor size, lymph node (LN) involvement, and extrathyroidal extension (ETE) were the significant prognostic factors for recurrence. Thyroid cancer-specific mortality was 1.4%, and the associated prognostic factors were older age, male sex, and LN involvement. For tumor recurrence, the hazard ratio (HR) for male sex decreased from 2.809 (95% CI, 1.497-5.269) in the pre-1989 period to 1.142 (95% CI, 0.736-1.772) in the post-1999 period. The pathologic characteristics, such as tumor size, LN involvement, and ETE, showed similar or increasing HRs over the time periods. For cancer-specific mortality, the HR for male sex decreased from 6.460 (95% CI, 1.714-24.348) in the pre-1990 period to 0.781 (95% CI, 0.083-7.379) in the post-1999 period. Conclusion: The risk for poor outcomes in PTC associated with male sex decreased over time; in contrast, the risk associated with pathologic characteristics remained the same or increased over time. These trends might be associated with recent changes in the characteristics of patients with thyroid cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Secular trends in the prognostic factors for papillary thyroid cancer

Choi

Lim

Ahn

et al. 2014

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Moreover, it could be confined for several years, therefore, it is easy to overlook. Extra-thyroid extension, late regional metastases, and distant metastases may be risk factors for early death from PTC [10]. In summary, the incidence tendency of PTC is increasing year by year, and now finding some biomarkers to assist diagnosis of PTC has become a hotspot.…”

Section: Introductionmentioning

confidence: 99%

Advances in Tumor Markers for the Early Diagnosis of Papillary Thyroid Carcinoma

Huang

Liu

Cao

et al. 2016

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Papillary Thyroid Carcinoma (PTC) is a common endocrine malignancy and mostly is found in women. Different pathological types of PTC have different biological behaviors. The hidden onset results in difficulties to diagnose the early PTC. With the development of the molecular biology, increasing the number of researchers is a focus on tumor markers. The sensitivity and specificity of these tumor markers are helpful for early diagnosis and therapy of PTC. This review is oriented towards the finding of the potent thyroid cancer markers have enhanced sensitivity and specificity, with diagnostic, prognostic and therapeutic efficiency.

show abstract

“…Furthermore, numerous previous studies have investigated potential molecular and cytological markers of biological behavior (3)(4)(5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

“…Factors that are known to significantly reduce PTC patient prognosis include age, male gender, large tumor size, extrathyroidal extension and metastases (3)(4)(5)(6).…”

Section: Introductionmentioning

confidence: 99%

Associations of the BRAF (V600E) mutation and p53 protein expression with clinicopathological features of papillary thyroid carcinomas patients

et al. 2015

View full text Add to dashboard Cite

Abstract. The BRAF (V600E) mutation is the most prevalent type of genetic alteration that has been identified in papillary thyroid carcinoma (PTC); in addition, previous immunohistochemical studies have revealed the overexpression of p53 protein in PTC. The aim of the present study was to investigate the prevalence of the BRAF (V600E) mutation and the expression of p53 in PTC, as well as to determine any associations between these two factors and the clinicopathological features of PTC. The study was performed on 66 PTC patients who underwent surgical tumor resection between January and December 2012. Polymerase chain reaction-based DNA amplification was used to analyze extracted DNA from the tumor specimens in order to determine the prevalence of the BRAF (V600E) mutation. In addition, immunohistochemical analysis was employed in order to evaluate the protein expression of p53 in sections of tumor tissue. Furthermore, statistical analysis was performed in order to determine any associations among the BRAF (V600E) mutation prevalence, p53 overexpression and the clinicopathological features of PTC patients, including age, gender, tumor size, multiplicity, lymph node metastasis and extrathyroidal extension. The results revealed that the BRAF (V600E) mutation was observed in 50 (75.8%) of the 66 PTC patients and overexpression of p53 was found in 52 (78.8%) of 66 cases. No significant correlations were observed between the BRAF (V600E) mutation or p53 protein overexpression and the clinicopathological features of patients. However, the BRAF (V600E) mutation demonstrated noteworthy, but non-significant, correlations with the overexpression of p53 (P=0.0854) and extrathyroidal extension (P= 0.0661). In addition, a significant correlation was observed between lymph node metastasis and bilaterality (P=0.0280). In conclusion, the present study demonstrated that the BRAF (V600E) mutation and overexpression of p53 were not significantly correlated with clinicopathological features of PTC, although notable associations were identified between BRAF (V600E) mutation and overexpression of p53 as well as extrathyroidal extension. In addition, lymph node metastasis was significantly associated with bilaterality.

show abstract

Early death from papillary thyroid carcinoma

Cited by 14 publications

References 27 publications

Secular trends in the prognostic factors for papillary thyroid cancer

Secular trends in the prognostic factors for papillary thyroid cancer

Advances in Tumor Markers for the Early Diagnosis of Papillary Thyroid Carcinoma

Associations of the BRAF (V600E) mutation and p53 protein expression with clinicopathological features of papillary thyroid carcinomas patients

Contact Info

Product

Resources

About